Tresiba (Insulin Degludec) Safety in Adults 65 and Older

Tresiba (insulin degludec) is an ultra-long-acting basal insulin analog administered as a once-daily subcutaneous injection, available in U-100 and U-200 pen formulations. The FDA has approved it for both type 1 and type 2 diabetes in adults without age restrictions. While structurally distinct from insulin glargine (Lantus, Basaglar, Toujeo) and the combination product insulin degludec/liraglutide (Xultophy), insulin degludec is frequently evaluated alongside glargine in older adults, as both serve as widely prescribed basal insulins in this population.

Why geriatric insulin safety needs its own conversation

Aging changes how the body handles insulin and how it tolerates a low glucose event. Renal clearance declines, which can prolong insulin exposure. Counter-regulatory hormone responses blunt with age, so the body is slower to self-correct a falling glucose. Polypharmacy is close to universal in this population, and several common drug classes interact with glucose control.

Hypoglycemia in an older adult is not just an inconvenience. It is a recognized trigger for falls, arrhythmia, and acute confusion, and repeated episodes have been linked in observational research to worse long-term cognitive and cardiovascular outcomes. Because of this, the American Diabetes Association's Standards of Care frame hypoglycemia avoidance as a primary goal in older adults and recommend individualized A1C targets, roughly in the range of below 7.5% for healthier older adults to below 8.0-8.5% for those with significant comorbidity, cognitive impairment, or limited life expectancy, rather than a single universal target (ADA Standards of Care).

Any basal insulin used in this age group should be judged on three things together: how much it lowers glucose, how predictable its action is day to day, and how forgiving it is when a dose is early, late, or missed.

What the trial evidence actually shows

DEVOTE. The DEVOTE cardiovascular outcomes trial randomized a large population of adults with type 2 diabetes and high cardiovascular risk to degludec or glargine U100 and followed them for roughly two years. It reported that degludec was non-inferior to glargine for major adverse cardiovascular events, and that rates of severe hypoglycemia, including severe nocturnal hypoglycemia, were meaningfully lower with degludec. This trial is widely cited as the primary cardiovascular and hypoglycemia safety dataset for degludec. Because the specific numeric rate reductions cannot be independently verified from the source material used to build this page, readers and clinicians who need exact figures for a specific decision should pull them directly from the published NEJM article (Marso et al., 2017) rather than relying on secondary summaries.

BRIGHT, in older participants specifically. The BRIGHT trial compared glargine U300 with insulin degludec and included analysis of glycemic control and hypoglycemia risk in older participants, which is more directly relevant to a 65-plus population than trial-wide averages (BRIGHT trial, older participants). This is the most age-specific comparative evidence available for this decision and should carry more weight for a geriatric-focused prescribing decision than headline results from the overall trial population. Clinicians making an individual prescribing decision for a patient 65 or older should review this analysis directly rather than assuming the overall-population effect size applies unchanged.

What is not established. No trial identified for this review directly measured falls, fractures, or dementia incidence as a primary outcome comparing degludec against another basal insulin in an exclusively geriatric cohort. The hypoglycemia-to-falls and hypoglycemia-to-cognitive-decline connections are supported by separate observational literature on hypoglycemia generally, not by degludec-specific outcome trials.

Pharmacokinetics: why the profile matters after 65

Degludec forms soluble multi-hexamer chains after injection, which slowly release insulin monomers over an extended period, producing a half-life in the range of 24 to 25 hours. This is longer than glargine U100 (roughly 12 hours) and glargine U300 (roughly 19 hours), and it produces a flatter, more stable glucose-lowering profile with less peak-to-trough swing.

Three consequences matter specifically for older patients:

Lower day-to-day variability. Trials comparing degludec with glargine U100 have reported reduced within-patient day-to-day fasting glucose variability with degludec. Less variability means fewer surprise lows and fewer surprise highs, which matters when a patient's meals, activity, and caregiver schedule are not perfectly consistent.

Dose-timing flexibility. The label supports dosing at any time of day provided at least 8 hours separate consecutive doses, based on flex-dosing interval trial data. This is a genuine practical advantage for patients whose schedule depends on a caregiver, home health aide, or facility staffing pattern, rather than a fixed clock time.

Renal handling. The label states no dose adjustment is required across renal impairment categories but recommends more frequent glucose monitoring at eGFR below 30 mL/min/1.73 m², since insulin clearance slows and hypoglycemia risk rises as kidney function declines (FDA label). Data specific to end-stage renal disease and dialysis populations are limited, and dose decisions in that setting should involve closer monitoring and, where available, endocrinology or nephrology input.

Falls: a plausible but indirect connection

Falls are a leading cause of injury and injury death in adults over 65 in the United States (CDC). Hypoglycemia is a recognized, modifiable contributor to falls in older adults with diabetes: low glucose impairs balance and reaction time and can provoke orthostatic symptoms through autonomic dysfunction.

No trial identified for this review has directly measured fall rates with degludec against a comparator insulin. The reasoning for a potential advantage is biologically plausible rather than directly proven: less nocturnal hypoglycemia should mean fewer episodes of impaired consciousness overnight, when fall risk from any cause is elevated, and lower day-to-day variability should reduce the abrupt cognitive and motor deficits that precede a fall. Readers should treat any statement that degludec "reduces falls" as an extrapolation from hypoglycemia data, not a demonstrated outcome.

Drug interactions and polypharmacy

Adults over 65 with type 2 diabetes commonly take multiple medications, and several interact with glucose control:

ACE inhibitors and ARBs, prescribed widely for hypertension and diabetic kidney disease, can increase insulin sensitivity.

Beta-blockers blunt the adrenergic warning signs of hypoglycemia, tremor and tachycardia, so a patient may progress toward confusion or seizure with less warning.

Sulfonylureas are the most common coprescribed agent that compounds hypoglycemia risk with basal insulin. Guideline bodies recommend considering a sulfonylurea dose reduction or discontinuation when basal insulin is started or intensified, particularly in patients over 65 (ADA Standards of Care).

Certain antibiotics, including some fluoroquinolones, have been associated with blood glucose disturbances in prescribing information and case reports. This claim needs direct verification against the specific drug's current label before being used for patient counseling, since the interaction and its magnitude vary by agent and by patient renal function.

Degludec's flatter pharmacokinetic profile does not remove these interaction risks. What it changes is the baseline: without a pronounced insulin peak, a glucose-lowering interaction is less likely to produce a sudden, deep nadir.

Deprescribing and target relaxation

Not every patient started on a given insulin regimen at 55 should remain on the identical regimen at 80. Deprescribing, the deliberate, supervised reduction or simplification of a medication regimen when risks begin to outweigh benefit, applies directly here.

Guideline bodies recommend relaxing A1C targets for older adults with significant comorbidity, cognitive impairment, or limited life expectancy, explicitly to reduce hypoglycemia and treatment burden. Simplifying a complex insulin regimen, for example moving from basal-bolus to basal-only, is a recognized strategy in this population when glycemic goals allow it.

When degludec itself is being tapered or stopped, for example after substantial weight loss on a GLP-1 receptor agonist, the long half-life means changes take time to show their full effect. Abrupt discontinuation in an insulin-dependent patient risks rebound hyperglycemia, and in type 1 diabetes, diabetic ketoacidosis. A cautious, individualized taper with frequent fasting glucose checks, done under clinician supervision, is the safer approach; there is no single validated taper schedule that applies to all patients, so specific dose-reduction increments should come from the prescribing clinician rather than a generic protocol.

Practical prescribing considerations

Starting degludec in an insulin-naive older adult follows the general basal-insulin principle: start low, titrate slowly. The label's general starting dose framework and titration should be confirmed against the current prescribing information, since dosing specifics can change and individualized starting doses for frail or renally impaired patients are a clinical judgment call, not a fixed formula.

For patients switching from glargine U100, dosing is generally unit-for-unit at the same total daily dose. Switching from glargine U300 typically involves a lower total unit dose due to bioavailability differences. Both conversions should be confirmed with the prescribing clinician and current label, not applied mechanically.

Continuous glucose monitoring adds meaningful safety value for insulin-treated older adults who can use the device or have a caregiver who can assist with it, and the ADA Standards of Care support its use in insulin-treated patients broadly (ADA Standards of Care). Objective time-below-range data give the clinician evidence for adjusting the dose or considering deprescribing, rather than relying on symptom recall alone, which is often unreliable in older adults.

The broader clinical framing worth keeping in mind: in geriatric diabetes care, the treatment itself is often the acute risk to manage, not just the underlying glucose level. An insulin that produces less variability and fewer nocturnal lows shifts that risk-benefit balance, but it does not eliminate the need for individualized target-setting, monitoring, and periodic reassessment.

Cognitive impairment and dementia

Observational research has linked recurrent hypoglycemia in older adults with diabetes to a higher risk of subsequent cognitive decline and dementia diagnosis, and separately, cognitive decline makes safe insulin self-management harder, creating a two-way risk relationship. The exact magnitude of this association, and how much any specific insulin's hypoglycemia advantage might modify it, has not been established by direct comparative trials and should not be quoted as a precise number without checking the primary study.

Practically, once-daily dosing without a fixed clock-time requirement and a prefilled pen that needs minimal dexterity or manual dose counting can lower the cognitive and motor demand on a patient with mild cognitive impairment or early dementia, and can make caregiver-administered dosing more feasible. This is a reasonable, evidence-consistent rationale for regimen simplification, not a claim that degludec treats or prevents dementia.

Nursing home and long-term care settings

Insulin timing in skilled nursing facilities depends heavily on staffing patterns and shift changes, which makes a rigid same-time-daily requirement operationally difficult. Degludec's validated flex-dosing window, a minimum of 8 hours between doses without loss of efficacy, is a practical fit for these settings. Diabetes management guidance for long-term care generally favors simplified, once-daily basal regimens over basal-bolus regimens when glycemic targets permit.

Hypoglycemia in nursing home residents is frequently missed because its symptoms, confusion, sedation, behavioral change, overlap with delirium or baseline cognitive impairment. Pairing a lower-hypoglycemia-risk basal insulin with structured glucose monitoring is a reasonable layered safety approach, though it does not replace individualized clinical assessment.

What is established, what is plausible, and what is not established

Established: Degludec has an extended, flatter pharmacokinetic profile compared with glargine formulations. Its label allows flexible dosing timing within an 8-hour minimum interval. Cardiovascular outcomes trial data support non-inferiority to glargine U100 for major cardiovascular events, with a lower reported rate of severe hypoglycemia in the overall trial population.

Plausible but not directly proven: That degludec's hypoglycemia advantage translates into fewer falls, fractures, or dementia diagnoses in real-world geriatric populations. These are reasonable extrapolations from general hypoglycemia-outcome literature, not from head-to-head degludec outcome trials measuring these endpoints.

Not established: A validated, universal taper protocol for discontinuing degludec in older adults; a head-to-head trial specifically measuring falls with degludec versus another basal insulin; precise magnitude of dementia risk reduction attributable to a specific insulin choice.

Decision framework: is degludec's flat profile the right fit for this patient?

This is not a substitute for individualized prescribing, but a structured way to organize the factors that actually change the decision for a specific older adult.

Step 1: Is hypoglycemia the dominant risk for this patient right now?

• If the patient has had a severe or nocturnal hypoglycemic episode, lives alone, or has hypoglycemia unawareness, a flatter basal insulin profile is more likely to matter clinically.
• If glucose control is currently inadequate with minimal hypoglycemia history, the priority may be efficacy and adherence rather than hypoglycemia reduction specifically.

Step 2: Does the patient's renal function change the monitoring plan?

• eGFR at or above 45: standard monitoring frequency is usually reasonable.
• eGFR between 30 and 45: increase monitoring frequency, especially after any dose change.
• eGFR below 30: closer monitoring is specifically recommended on the label; involve nephrology input if the regimen is complex.

Step 3: Does the patient's cognitive and caregiving situation favor flexible timing?

• Independent, cognitively intact, consistent schedule: timing flexibility is a convenience, not a safety necessity.
• Caregiver-dependent, variable visit windows, or facility-based care: flexible dosing interval becomes an operational safety feature, not just a convenience.

Step 4: What is the realistic glycemic target for this patient?

• Healthy, few comorbidities, good functional status: target consistent with a lower A1C range per ADA guidance.
• Multiple comorbidities, cognitive impairment, or limited life expectancy: relaxed target, explicit prioritization of avoiding hypoglycemia over tight control.

Step 5: Is this a deprescribing conversation instead of a insulin-selection conversation?

• Significant unintentional weight loss, new GLP-1 receptor agonist use, recurrent unexplained lows, or a shift in goals of care are all triggers to reassess whether the current total insulin dose, or insulin itself, is still appropriate, rather than simply switching insulin brands.

When this framework does not apply: a patient with type 1 diabetes, a patient with recurrent diabetic ketoacidosis, or a patient with unstable renal function requires individualized specialist input; this structure is meant for the more common stable type 2 diabetes basal-insulin decision, not for complex or unstable cases.